Zic family member 5 promotes survival in human pancreatic cancer and cholangiocarcinoma cells.

Apoptosis Cholangiocarcinoma Gemcitabine Pancreatic ductal adenocarcinoma STAT3 ZIC5

Journal

Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 26 11 2021
revised: 20 05 2022
accepted: 23 05 2022
entrez: 7 6 2022
pubmed: 8 6 2022
medline: 8 6 2022
Statut: epublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are malignant tumors with poor prognosis because of the limited effectiveness of traditional chemotherapy and few effective molecular therapeutic agents. Here, we determined the essential roles of Zic family member 5 (

Identifiants

pubmed: 35669984
doi: 10.1016/j.bbrep.2022.101289
pii: S2405-5808(22)00089-9
pmc: PMC9166430
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101289

Informations de copyright

© 2022 The Authors. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

J Cell Sci. 2021 May 1;134(9):
pubmed: 33771929
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Gastroenterology. 2007 Jan;132(1):384-96
pubmed: 17241887
Biochem Biophys Res Commun. 2018 May 23;499(4):765-771
pubmed: 29605301
Biochem Biophys Res Commun. 2016 Oct 21;479(3):502-509
pubmed: 27663664
J Cell Biochem. 2019 Mar;120(3):3780-3789
pubmed: 30382592
Cancer Res. 2017 Jan 15;77(2):366-377
pubmed: 27671679
Cancer Res. 2018 Nov 1;78(21):6235-6246
pubmed: 30154150
Diagnostics (Basel). 2021 Feb 06;11(2):
pubmed: 33562094
Cancer Sci. 2017 Dec;108(12):2405-2412
pubmed: 29024195
Cancer Cell. 2011 Apr 12;19(4):441-55
pubmed: 21481787
Biochem Biophys Res Commun. 2018 Sep 10;503(3):2173-2179
pubmed: 30086882
Liver Int. 2019 May;39 Suppl 1:43-62
pubmed: 30903728
Bioinformatics. 2018 Feb 15;34(4):713-715
pubmed: 29028907
Cancer Res. 2018 Jun 15;78(12):3293-3305
pubmed: 29572224

Auteurs

Reiko Satow (R)

Laboratory of Genome and Biosignals, Tokyo University of Pharmacy and Life Sciences, Hachioji-shi, Tokyo, 192-0392, Japan.

Yuna Aiga (Y)

Laboratory of Genome and Biosignals, Tokyo University of Pharmacy and Life Sciences, Hachioji-shi, Tokyo, 192-0392, Japan.

Takeru Watanabe (T)

Laboratory of Genome and Biosignals, Tokyo University of Pharmacy and Life Sciences, Hachioji-shi, Tokyo, 192-0392, Japan.

Nako Ishizuka (N)

Laboratory of Genome and Biosignals, Tokyo University of Pharmacy and Life Sciences, Hachioji-shi, Tokyo, 192-0392, Japan.

Atsuko Yoneda (A)

Laboratory of Genome and Biosignals, Tokyo University of Pharmacy and Life Sciences, Hachioji-shi, Tokyo, 192-0392, Japan.

Kiyoko Fukami (K)

Laboratory of Genome and Biosignals, Tokyo University of Pharmacy and Life Sciences, Hachioji-shi, Tokyo, 192-0392, Japan.

Classifications MeSH